Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

norgine b.v. antonio vivaldistraat 150 1083 hp amsterdam - kaliumchloride 1,9 mg/ml ; macrogol 3350 525 mg/ml ; natriumchloride 14 mg/ml ; natriumwaterstofcarbonaat (e 500 (ii)) 7,1 mg/ml - poeder voor drank - acesulfaam kalium (e 950) ; benzylalcohol (e 1519) 1,8 mg/ml ; ethanol 3 mg/ml ; ethylparahydroxybenzoaat (e 214) ; methylparahydroxybenzoaat (e 218) ; sinaasappelsmaakstof ; sucralose (e 955) ; water, gezuiverd, - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

norgine - kaliumchloride ; macrogol 3350 ; natriumchloride ; natriumwaterstofcarbonaat (e 500 (ii)) - poeder voor drank - acesulfaam kalium (e 950) ; benzylalcohol (e 1519) 1,8 mg/ml ; ethanol 3 mg/ml ; ethylparahydroxybenzoaat (e 214) ; methylparahydroxybenzoaat (e 218) ; sinaasappelsmaakstof ; sucralose (e 955) ; water, gezuiverd, - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. - kaliumchloride; macrogol 3350; natriumchloride; natriumwaterstofcarbonaat (e 500 (ii)); samenstelling overeenkomend met chloride (cl-); kalium (k+); natrium (na+); waterstofcarbonaat (hco3-); - poeder voor drank - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. - kaliumchloride ; macrogol 3350 ; natriumchloride ; natriumwaterstofcarbonaat (e 500 (ii)) ; samenstelling overeenkomend met chloride (cl-) ; kalium (k+) ; natrium (na+) ; waterstofcarbonaat (hco3-) - poeder voor oraal gebruik - geen hulpstoffen, - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

norgine b.v. antonio vivaldistraat 150 1083 hp amsterdam - kaliumchloride 50,2 mg/stuk ; macrogol 3350 13,13 g/stuk ; natriumchloride 350,8 mg/stuk ; natriumwaterstofcarbonaat (e 500 (ii)) 178,6 mg/stuk ; samenstelling overeenkomend met chloride (cl-) 53 mmol/l ; kalium (k+) 5,4 mmol/l ; natrium (na+) 65 mmol/l ; waterstofcarbonaat (hco3-) 17 mmol/l - poeder voor drank - geen hulpstoffen, - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

norgine cross towers, antonio vivaldistraat 150 1083 hp amsterdam - kaliumchloride 2,01 mg/ml ; macrogol 3350 525 mg/ml ; natriumchloride 14,03 mg/ml ; natriumwaterstofcarbonaat (e 500 (ii)) 7,14 mg/ml ; samenstelling overeenkomend met chloride (cl-) 267 mmol/l ; kalium (k+) 27 mmol/l ; natrium (na+) 325 mmol/l ; waterstofcarbonaat (hco3-) 85 mmol/l - drank - aardbeien-bananensmaakstof ; propyleenglycol (e 1520) ; sucralose (e 955) ; water, gezuiverd - macrogol, combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - kaliumchloride ; macrogol 3350 ; natriumchloride ; natriumwaterstofcarbonaat (e 500 (ii)) ; samenstelling overeenkomend met chloride (cl-) ; kalium (k+) ; natrium (na+) ; waterstofcarbonaat (hco3-) - poeder voor drank - geen hulpstoffen - macrogol, combinations

Europese Unie - Nederlands - EMA (European Medicines Agency)

alfasigma s.p.a. - methylthioniniumchloride - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Europese Unie - Nederlands - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.